Caris Life Sciences, Inc.
CAI
$29.85
$0.943.25%
NASDAQ
| 03/31/2025 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 120.92M | 80.68M | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 120.92M | 80.68M | |||
| Cost of Revenue | 63.85M | 54.56M | |||
| Gross Profit | 57.06M | 26.11M | |||
| SG&A Expenses | 91.95M | 83.96M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 178.87M | 172.90M | |||
| Operating Income | -57.95M | -92.23M | |||
| Income Before Tax | -102.58M | -111.03M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -102.58M | -111.03M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -102.58M | -111.03M | |||
| EBIT | -57.95M | -92.23M | |||
| EBITDA | -50.91M | -74.52M | |||
| EPS Basic | -3.57 | -3.80 | |||
| Normalized Basic EPS | -1.80 | -1.97 | |||
| EPS Diluted | -3.57 | -3.80 | |||
| Normalized Diluted EPS | -1.80 | -1.97 | |||
| Average Basic Shares Outstanding | 35.62M | 35.31M | |||
| Average Diluted Shares Outstanding | 35.62M | 35.31M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||